Bioartificial Intelligence™                        Human Therapeutic Antibodies

​​​​​

About 200 therapeutic antibodies ('tAbs") were approved or under regulatory review in the US and Europe by the end of 2023 (Antibody Society, December 2023), each generated with in vivo platforms such as normal or human Ig transgenic animals, in vitro platforms such as phage display, or cloning from humans.

​

Artificial Intelligence ("AI") is increasingly being used to create tAbs via deep learning using antibody and other protein "training sets" from public or private sources. Established AI models can be used to evaluate tAbs not present during the training stage or generate entirely new tAbs ("Generative AI").

​​​​

​​​Abvivo's Bioartificial Intelligence™ encompasses the use of primary tAbs as AI input to generate high-performance mono-, bi-, and multi-specific tAbs. ​Contact bl@abvivo.com for more information.